Global Oral Hypoglycemic Drugs Market Research Report 2023

The global Oral Hypoglycemic Drugs market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

North American market for Oral Hypoglycemic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Oral Hypoglycemic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global manufacturers of Oral Hypoglycemic Drugs include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals and Novo Nordisk, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Oral Hypoglycemic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oral Hypoglycemic Drugs.

The Oral Hypoglycemic Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oral Hypoglycemic Drugs market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Oral Hypoglycemic Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

1.1 Product Overview and Scope of Oral Hypoglycemic Drugs

1.2 Oral Hypoglycemic Drugs Segment by Type

1.2.1 Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2023-2029)

1.2.2 Sulfonylureas (SU)

1.2.3 Double Guanidine

1.2.4 Glucosidase Inhibitor

1.2.5 Insulin Synergist

1.3 Oral Hypoglycemic Drugs Segment by Application

1.3.1 Global Oral Hypoglycemic Drugs Market Value by Application: (2023-2029)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Oral Hypoglycemic Drugs Market Size Estimates and Forecasts

1.4.1 Global Oral Hypoglycemic Drugs Revenue 2018-2029

1.4.2 Global Oral Hypoglycemic Drugs Sales 2018-2029

1.4.3 Global Oral Hypoglycemic Drugs Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturers (2018-2023)

2.2 Global Oral Hypoglycemic Drugs Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Oral Hypoglycemic Drugs Average Price by Manufacturers (2018-2023)

2.4 Global Oral Hypoglycemic Drugs Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Oral Hypoglycemic Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Oral Hypoglycemic Drugs, Product Type & Application

2.7 Oral Hypoglycemic Drugs Market Competitive Situation and Trends

2.7.1 Oral Hypoglycemic Drugs Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Oral Hypoglycemic Drugs Players Market Share by Revenue

2.7.3 Global Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Oral Hypoglycemic Drugs Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Oral Hypoglycemic Drugs Global Oral Hypoglycemic Drugs Sales by Region: 2018-2029

3.2.1 Global Oral Hypoglycemic Drugs Sales by Region: 2018-2023

3.2.2 Global Oral Hypoglycemic Drugs Sales by Region: 2024-2029

3.3 Global Oral Hypoglycemic Drugs Global Oral Hypoglycemic Drugs Revenue by Region: 2018-2029

3.3.1 Global Oral Hypoglycemic Drugs Revenue by Region: 2018-2023

3.3.2 Global Oral Hypoglycemic Drugs Revenue by Region: 2024-2029

3.4 North America Oral Hypoglycemic Drugs Market Facts & Figures by Country

3.4.1 North America Oral Hypoglycemic Drugs Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Oral Hypoglycemic Drugs Sales by Country (2018-2029)

3.4.3 North America Oral Hypoglycemic Drugs Revenue by Country (2018-2029)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Oral Hypoglycemic Drugs Market Facts & Figures by Country

3.5.1 Europe Oral Hypoglycemic Drugs Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Oral Hypoglycemic Drugs Sales by Country (2018-2029)

3.5.3 Europe Oral Hypoglycemic Drugs Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Oral Hypoglycemic Drugs Market Facts & Figures by Country

3.6.1 Asia Pacific Oral Hypoglycemic Drugs Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Oral Hypoglycemic Drugs Sales by Country (2018-2029)

3.6.3 Asia Pacific Oral Hypoglycemic Drugs Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Oral Hypoglycemic Drugs Market Facts & Figures by Country

3.7.1 Latin America Oral Hypoglycemic Drugs Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Oral Hypoglycemic Drugs Sales by Country (2018-2029)

3.7.3 Latin America Oral Hypoglycemic Drugs Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Oral Hypoglycemic Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Oral Hypoglycemic Drugs Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Oral Hypoglycemic Drugs Sales by Country (2018-2029)

3.8.3 Middle East and Africa Oral Hypoglycemic Drugs Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Oral Hypoglycemic Drugs Sales by Type (2018-2029)

4.1.1 Global Oral Hypoglycemic Drugs Sales by Type (2018-2023)

4.1.2 Global Oral Hypoglycemic Drugs Sales by Type (2024-2029)

4.1.3 Global Oral Hypoglycemic Drugs Sales Market Share by Type (2018-2029)

4.2 Global Oral Hypoglycemic Drugs Revenue by Type (2018-2029)

4.2.1 Global Oral Hypoglycemic Drugs Revenue by Type (2018-2023)

4.2.2 Global Oral Hypoglycemic Drugs Revenue by Type (2024-2029)

4.2.3 Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2018-2029)

4.3 Global Oral Hypoglycemic Drugs Price by Type (2018-2029)

5.1 Global Oral Hypoglycemic Drugs Sales by Application (2018-2029)

5.1.1 Global Oral Hypoglycemic Drugs Sales by Application (2018-2023)

5.1.2 Global Oral Hypoglycemic Drugs Sales by Application (2024-2029)

5.1.3 Global Oral Hypoglycemic Drugs Sales Market Share by Application (2018-2029)

5.2 Global Oral Hypoglycemic Drugs Revenue by Application (2018-2029)

5.2.1 Global Oral Hypoglycemic Drugs Revenue by Application (2018-2023)

5.2.2 Global Oral Hypoglycemic Drugs Revenue by Application (2024-2029)

5.2.3 Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2018-2029)

5.3 Global Oral Hypoglycemic Drugs Price by Application (2018-2029)

6.1 Pfizer

6.1.1 Pfizer Corporation Information

6.1.2 Pfizer Description and Business Overview

6.1.3 Pfizer Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.1.4 Pfizer Oral Hypoglycemic Drugs Product Portfolio

6.1.5 Pfizer Recent Developments/Updates

6.2 AstraZeneca

6.2.1 AstraZeneca Corporation Information

6.2.2 AstraZeneca Description and Business Overview

6.2.3 AstraZeneca Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.2.4 AstraZeneca Oral Hypoglycemic Drugs Product Portfolio

6.2.5 AstraZeneca Recent Developments/Updates

6.3 Johnson & Johnson

6.3.1 Johnson & Johnson Corporation Information

6.3.2 Johnson & Johnson Description and Business Overview

6.3.3 Johnson & Johnson Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Johnson & Johnson Oral Hypoglycemic Drugs Product Portfolio

6.3.5 Johnson & Johnson Recent Developments/Updates

6.4 GlaxoSmithKline

6.4.1 GlaxoSmithKline Corporation Information

6.4.2 GlaxoSmithKline Description and Business Overview

6.4.3 GlaxoSmithKline Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.4.4 GlaxoSmithKline Oral Hypoglycemic Drugs Product Portfolio

6.4.5 GlaxoSmithKline Recent Developments/Updates

6.5 Merck & Co

6.5.1 Merck & Co Corporation Information

6.5.2 Merck & Co Description and Business Overview

6.5.3 Merck & Co Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Merck & Co Oral Hypoglycemic Drugs Product Portfolio

6.5.5 Merck & Co Recent Developments/Updates

6.6 Eli Lilly

6.6.1 Eli Lilly Corporation Information

6.6.2 Eli Lilly Description and Business Overview

6.6.3 Eli Lilly Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Eli Lilly Oral Hypoglycemic Drugs Product Portfolio

6.6.5 Eli Lilly Recent Developments/Updates

6.7 Sanofi

6.6.1 Sanofi Corporation Information

6.6.2 Sanofi Description and Business Overview

6.6.3 Sanofi Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Sanofi Oral Hypoglycemic Drugs Product Portfolio

6.7.5 Sanofi Recent Developments/Updates

6.8 Takeda Pharmaceuticals

6.8.1 Takeda Pharmaceuticals Corporation Information

6.8.2 Takeda Pharmaceuticals Description and Business Overview

6.8.3 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.8.4 Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product Portfolio

6.8.5 Takeda Pharmaceuticals Recent Developments/Updates

6.9 Novo Nordisk

6.9.1 Novo Nordisk Corporation Information

6.9.2 Novo Nordisk Description and Business Overview

6.9.3 Novo Nordisk Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.9.4 Novo Nordisk Oral Hypoglycemic Drugs Product Portfolio

6.9.5 Novo Nordisk Recent Developments/Updates

6.10 Servier Laboratories

6.10.1 Servier Laboratories Corporation Information

6.10.2 Servier Laboratories Description and Business Overview

6.10.3 Servier Laboratories Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.10.4 Servier Laboratories Oral Hypoglycemic Drugs Product Portfolio

6.10.5 Servier Laboratories Recent Developments/Updates

6.11 Boehringer Ingelheim

6.11.1 Boehringer Ingelheim Corporation Information

6.11.2 Boehringer Ingelheim Oral Hypoglycemic Drugs Description and Business Overview

6.11.3 Boehringer Ingelheim Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.11.4 Boehringer Ingelheim Oral Hypoglycemic Drugs Product Portfolio

6.11.5 Boehringer Ingelheim Recent Developments/Updates

6.12 Bristol-Myers Squibb

6.12.1 Bristol-Myers Squibb Corporation Information

6.12.2 Bristol-Myers Squibb Oral Hypoglycemic Drugs Description and Business Overview

6.12.3 Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales, Revenue and Gross Margin (2018-2023)

6.12.4 Bristol-Myers Squibb Oral Hypoglycemic Drugs Product Portfolio

6.12.5 Bristol-Myers Squibb Recent Developments/Updates

7.1 Oral Hypoglycemic Drugs Industry Chain Analysis

7.2 Oral Hypoglycemic Drugs Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Oral Hypoglycemic Drugs Production Mode & Process

7.4 Oral Hypoglycemic Drugs Sales and Marketing

7.4.1 Oral Hypoglycemic Drugs Sales Channels

7.4.2 Oral Hypoglycemic Drugs Distributors

7.5 Oral Hypoglycemic Drugs Customers

8.1 Oral Hypoglycemic Drugs Industry Trends

8.2 Oral Hypoglycemic Drugs Market Drivers

8.3 Oral Hypoglycemic Drugs Market Challenges

8.4 Oral Hypoglycemic Drugs Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Oral Hypoglycemic Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Oral Hypoglycemic Drugs Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Oral Hypoglycemic Drugs Sales (K Units) of Key Manufacturers (2018-2023)

    Table 5. Global Oral Hypoglycemic Drugs Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Oral Hypoglycemic Drugs Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Oral Hypoglycemic Drugs Average Price (US$/Unit) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Oral Hypoglycemic Drugs, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Oral Hypoglycemic Drugs, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Oral Hypoglycemic Drugs, Product Type & Application

    Table 12. Global Key Manufacturers of Oral Hypoglycemic Drugs, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Oral Hypoglycemic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oral Hypoglycemic Drugs as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Oral Hypoglycemic Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Oral Hypoglycemic Drugs Sales by Region (2018-2023) & (K Units)

    Table 18. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2018-2023)

    Table 19. Global Oral Hypoglycemic Drugs Sales by Region (2024-2029) & (K Units)

    Table 20. Global Oral Hypoglycemic Drugs Sales Market Share by Region (2024-2029)

    Table 21. Global Oral Hypoglycemic Drugs Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2018-2023)

    Table 23. Global Oral Hypoglycemic Drugs Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Oral Hypoglycemic Drugs Revenue Market Share by Region (2024-2029)

    Table 25. North America Oral Hypoglycemic Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Oral Hypoglycemic Drugs Sales by Country (2018-2023) & (K Units)

    Table 27. North America Oral Hypoglycemic Drugs Sales by Country (2024-2029) & (K Units)

    Table 28. North America Oral Hypoglycemic Drugs Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Oral Hypoglycemic Drugs Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Oral Hypoglycemic Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Oral Hypoglycemic Drugs Sales by Country (2018-2023) & (K Units)

    Table 32. Europe Oral Hypoglycemic Drugs Sales by Country (2024-2029) & (K Units)

    Table 33. Europe Oral Hypoglycemic Drugs Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Oral Hypoglycemic Drugs Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2018-2023) & (K Units)

    Table 37. Asia Pacific Oral Hypoglycemic Drugs Sales by Region (2024-2029) & (K Units)

    Table 38. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Oral Hypoglycemic Drugs Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Oral Hypoglycemic Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Oral Hypoglycemic Drugs Sales by Country (2018-2023) & (K Units)

    Table 42. Latin America Oral Hypoglycemic Drugs Sales by Country (2024-2029) & (K Units)

    Table 43. Latin America Oral Hypoglycemic Drugs Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Oral Hypoglycemic Drugs Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Oral Hypoglycemic Drugs Sales by Country (2018-2023) & (K Units)

    Table 47. Middle East & Africa Oral Hypoglycemic Drugs Sales by Country (2024-2029) & (K Units)

    Table 48. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Oral Hypoglycemic Drugs Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Oral Hypoglycemic Drugs Sales (K Units) by Type (2018-2023)

    Table 51. Global Oral Hypoglycemic Drugs Sales (K Units) by Type (2024-2029)

    Table 52. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2018-2023)

    Table 53. Global Oral Hypoglycemic Drugs Sales Market Share by Type (2024-2029)

    Table 54. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2018-2023)

    Table 57. Global Oral Hypoglycemic Drugs Revenue Market Share by Type (2024-2029)

    Table 58. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2018-2023)

    Table 59. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2024-2029)

    Table 60. Global Oral Hypoglycemic Drugs Sales (K Units) by Application (2018-2023)

    Table 61. Global Oral Hypoglycemic Drugs Sales (K Units) by Application (2024-2029)

    Table 62. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2018-2023)

    Table 63. Global Oral Hypoglycemic Drugs Sales Market Share by Application (2024-2029)

    Table 64. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Oral Hypoglycemic Drugs Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2018-2023)

    Table 67. Global Oral Hypoglycemic Drugs Revenue Market Share by Application (2024-2029)

    Table 68. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2018-2023)

    Table 69. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2024-2029)

    Table 70. Pfizer Corporation Information

    Table 71. Pfizer Description and Business Overview

    Table 72. Pfizer Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 73. Pfizer Oral Hypoglycemic Drugs Product

    Table 74. Pfizer Recent Developments/Updates

    Table 75. AstraZeneca Corporation Information

    Table 76. AstraZeneca Description and Business Overview

    Table 77. AstraZeneca Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 78. AstraZeneca Oral Hypoglycemic Drugs Product

    Table 79. AstraZeneca Recent Developments/Updates

    Table 80. Johnson & Johnson Corporation Information

    Table 81. Johnson & Johnson Description and Business Overview

    Table 82. Johnson & Johnson Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 83. Johnson & Johnson Oral Hypoglycemic Drugs Product

    Table 84. Johnson & Johnson Recent Developments/Updates

    Table 85. GlaxoSmithKline Corporation Information

    Table 86. GlaxoSmithKline Description and Business Overview

    Table 87. GlaxoSmithKline Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 88. GlaxoSmithKline Oral Hypoglycemic Drugs Product

    Table 89. GlaxoSmithKline Recent Developments/Updates

    Table 90. Merck & Co Corporation Information

    Table 91. Merck & Co Description and Business Overview

    Table 92. Merck & Co Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 93. Merck & Co Oral Hypoglycemic Drugs Product

    Table 94. Merck & Co Recent Developments/Updates

    Table 95. Eli Lilly Corporation Information

    Table 96. Eli Lilly Description and Business Overview

    Table 97. Eli Lilly Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 98. Eli Lilly Oral Hypoglycemic Drugs Product

    Table 99. Eli Lilly Recent Developments/Updates

    Table 100. Sanofi Corporation Information

    Table 101. Sanofi Description and Business Overview

    Table 102. Sanofi Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 103. Sanofi Oral Hypoglycemic Drugs Product

    Table 104. Sanofi Recent Developments/Updates

    Table 105. Takeda Pharmaceuticals Corporation Information

    Table 106. Takeda Pharmaceuticals Description and Business Overview

    Table 107. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 108. Takeda Pharmaceuticals Oral Hypoglycemic Drugs Product

    Table 109. Takeda Pharmaceuticals Recent Developments/Updates

    Table 110. Novo Nordisk Corporation Information

    Table 111. Novo Nordisk Description and Business Overview

    Table 112. Novo Nordisk Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 113. Novo Nordisk Oral Hypoglycemic Drugs Product

    Table 114. Novo Nordisk Recent Developments/Updates

    Table 115. Servier Laboratories Corporation Information

    Table 116. Servier Laboratories Description and Business Overview

    Table 117. Servier Laboratories Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 118. Servier Laboratories Oral Hypoglycemic Drugs Product

    Table 119. Servier Laboratories Recent Developments/Updates

    Table 120. Boehringer Ingelheim Corporation Information

    Table 121. Boehringer Ingelheim Description and Business Overview

    Table 122. Boehringer Ingelheim Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 123. Boehringer Ingelheim Oral Hypoglycemic Drugs Product

    Table 124. Boehringer Ingelheim Recent Developments/Updates

    Table 125. Bristol-Myers Squibb Corporation Information

    Table 126. Bristol-Myers Squibb Description and Business Overview

    Table 127. Bristol-Myers Squibb Oral Hypoglycemic Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 128. Bristol-Myers Squibb Oral Hypoglycemic Drugs Product

    Table 129. Bristol-Myers Squibb Recent Developments/Updates

    Table 130. Key Raw Materials Lists

    Table 131. Raw Materials Key Suppliers Lists

    Table 132. Oral Hypoglycemic Drugs Distributors List

    Table 133. Oral Hypoglycemic Drugs Customers List

    Table 134. Oral Hypoglycemic Drugs Market Trends

    Table 135. Oral Hypoglycemic Drugs Market Drivers

    Table 136. Oral Hypoglycemic Drugs Market Challenges

    Table 137. Oral Hypoglycemic Drugs Market Restraints

    Table 138. Research Programs/Design for This Report

    Table 139. Key Data Information from Secondary Sources

    Table 140. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Oral Hypoglycemic Drugs

    Figure 2. Global Oral Hypoglycemic Drugs Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Oral Hypoglycemic Drugs Market Share by Type in 2022 & 2029

    Figure 4. Sulfonylureas (SU) Product Picture

    Figure 5. Double Guanidine Product Picture

    Figure 6. Glucosidase Inhibitor Product Picture

    Figure 7. Insulin Synergist Product Picture

    Figure 8. Global Oral Hypoglycemic Drugs Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 9. Global Oral Hypoglycemic Drugs Market Share by Application in 2022 & 2029

    Figure 10. Hospital

    Figure 11. Clinic

    Figure 12. Others

    Figure 13. Global Oral Hypoglycemic Drugs Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 14. Global Oral Hypoglycemic Drugs Market Size (2018-2029) & (US$ Million)

    Figure 15. Global Oral Hypoglycemic Drugs Sales (2018-2029) & (K Units)

    Figure 16. Global Oral Hypoglycemic Drugs Average Price (US$/Unit) & (2018-2029)

    Figure 17. Oral Hypoglycemic Drugs Report Years Considered

    Figure 18. Oral Hypoglycemic Drugs Sales Share by Manufacturers in 2022

    Figure 19. Global Oral Hypoglycemic Drugs Revenue Share by Manufacturers in 2022

    Figure 20. The Global 5 and 10 Largest Oral Hypoglycemic Drugs Players: Market Share by Revenue in 2022

    Figure 21. Oral Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 22. Global Oral Hypoglycemic Drugs Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 23. North America Oral Hypoglycemic Drugs Sales Market Share by Country (2018-2029)

    Figure 24. North America Oral Hypoglycemic Drugs Revenue Market Share by Country (2018-2029)

    Figure 25. U.S. Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 26. Canada Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 27. Europe Oral Hypoglycemic Drugs Sales Market Share by Country (2018-2029)

    Figure 28. Europe Oral Hypoglycemic Drugs Revenue Market Share by Country (2018-2029)

    Figure 29. Germany Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. France Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. U.K. Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Italy Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 33. Russia Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 34. Asia Pacific Oral Hypoglycemic Drugs Sales Market Share by Region (2018-2029)

    Figure 35. Asia Pacific Oral Hypoglycemic Drugs Revenue Market Share by Region (2018-2029)

    Figure 36. China Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. Japan Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. South Korea Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. India Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. Australia Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Taiwan Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Indonesia Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 43. Thailand Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 44. Malaysia Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 45. Philippines Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Latin America Oral Hypoglycemic Drugs Sales Market Share by Country (2018-2029)

    Figure 47. Latin America Oral Hypoglycemic Drugs Revenue Market Share by Country (2018-2029)

    Figure 48. Mexico Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 49. Brazil Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 50. Argentina Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. Middle East & Africa Oral Hypoglycemic Drugs Sales Market Share by Country (2018-2029)

    Figure 52. Middle East & Africa Oral Hypoglycemic Drugs Revenue Market Share by Country (2018-2029)

    Figure 53. Turkey Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 54. Saudi Arabia Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 55. UAE Oral Hypoglycemic Drugs Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 56. Global Sales Market Share of Oral Hypoglycemic Drugs by Type (2018-2029)

    Figure 57. Global Revenue Market Share of Oral Hypoglycemic Drugs by Type (2018-2029)

    Figure 58. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Type (2018-2029)

    Figure 59. Global Sales Market Share of Oral Hypoglycemic Drugs by Application (2018-2029)

    Figure 60. Global Revenue Market Share of Oral Hypoglycemic Drugs by Application (2018-2029)

    Figure 61. Global Oral Hypoglycemic Drugs Price (US$/Unit) by Application (2018-2029)

    Figure 62. Oral Hypoglycemic Drugs Value Chain

    Figure 63. Oral Hypoglycemic Drugs Production Process

    Figure 64. Channels of Distribution (Direct Vs Distribution)

    Figure 65. Distributors Profiles

    Figure 66. Bottom-up and Top-down Approaches for This Report

    Figure 67. Data Triangulation

    Figure 68. Key Executives Interviewed